Amoxicillin–Clavulanate-Induced Liver Injury

Digestive Diseases and Sciences

Volumn 61, Issue 8, 2016, Pages 2406-2416

  deLemos, Andrew S ^a   Ghabril, Marwan ^b   Rockey, Don C ^c   Gu, Jiezhun ^d   Barnhart, Huiman X ^d   Fontana, Robert J ^e   Kleiner, David E ^f   Bonkovsky, Herbert L ^g  

^a CAROLINAS MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Allergy; Amoxicillin; Augmentin; Clavulanic acid; Drug induced liver injury; Liver toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; BILIRUBIN;

ADULT; ARTICLE; CHILD; CHOLESTASIS; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; JAUNDICE; LABORATORY TEST; LIVER BIOPSY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCHOOL CHILD; PRIORITY JOURNAL; TOXIC HEPATITIS; YOUNG ADULT; AFRICAN AMERICAN; AGE; BLOOD; CAUCASIAN; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; ETHNIC GROUP; HISPANIC; JAUNDICE, OBSTRUCTIVE; LIVER; PATHOLOGY; PROSPECTIVE STUDY; REGISTER; SEX RATIO; STATISTICS AND NUMERICAL DATA; TIME FACTOR; UNITED STATES;

AFRICAN AMERICANS; AGE FACTORS; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BILIRUBIN; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHOLESTASIS; COHORT STUDIES; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; JAUNDICE; JAUNDICE, OBSTRUCTIVE; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; SEX DISTRIBUTION; TIME FACTORS; UNITED STATES;

EID: 84961786421     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-016-4121-6     Document Type: Article

References (27)

1. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924–1934, 1934 e1921–1924.
2. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521.
3. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425, 1425 e1411–1413; quiz e1419–e1420.
4. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146:914–928.
5. Lewis JH, Zimmerman HJ. Drug- and chemical-induced cholestasis. Clin Liver Dis. 1999;3:433–464, vii.
6. Mohi-ud-din R, Lewis JH. Drug- and chemical-induced cholestasis. Clin Liver Dis. 2004;8:95–132, vii.
7. Jakab SS, West AB, Meighan DM, Brown RS Jr, Hale WB. Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World J Gastroenterol. 2007;13:6087–6089.
8. Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29:364–372.
9. Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci. 2005;50:1785–1790.
10. Limauro DL, Chan-Tompkins NH, Carter RW, Brodmerkel GJ Jr, Agrawal RM. Amoxicillin/clavulanate-associated hepatic failure with progression to Stevens–Johnson syndrome. Ann Pharmacother. 1999;33:560–564.
11. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55–68.
12. Fontana RJ, Hayashi PH, Barnhart H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110:1450–1459.
13. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117–2126.
14. Alqahtani SA, Kleiner DE, Ghabril M, et al. Identification and characterization of cefazolin-induced liver injury. Clin Gastroenterol Hepatol. 2015;13:1328–1336.e2.
15. Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin–clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44:850–856.
16. Reddy KR, Brillant P, Schiff ER. Amoxicillin–clavulanate potassium-associated cholestasis. Gastroenterology. 1989;96:1135–1141.
17. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin–clavulanate–induced hepatitis. Gastroenterology. 1999;117:1181–1186.
18. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut. 1992;33:368–371.
19. Foureau DM, Walling TL, Maddukuri V, et al. Comparative analysis of portal hepatic infiltrating leukocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol. 2015;180:40–51.
20. Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin–clavulanate–induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141:338–347.
21. Stephens C, Lopez-Nevot MA, Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin–clavulanate hepatotoxicity. PLoS One. 2013;8:e68111.
22. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41:816–819.
23. Urban TJ, Shen Y, Stolz A, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics. 2012;22:784–795.
24. de Haan F. Stricker BH [Liver damage associated with the combination drug amoxicillin-clavulanic acid (Augmentin)]. Ned Tijdschr Geneeskd. 1997;141:1298–1301.
25. Thomson JA, Fairley CK, Ugoni AM, et al. Risk factors for the development of amoxycillin-clavulanic acid associated jaundice. Med J Aust. 1995;162:638–640.
26. O’Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47:717–720.
27. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med. 1996;156:1327–1332.